The Shift from Small Molecules to Biologics Is Complicated. ADCs Make It Even More Complex.
The pharmaceutical industry is in the midst of one of the most significant manufacturing transformations in its history. For decades, success was built on small molecule drugs—products with relatively well-understood chemistry, established manufacturing processes, and predictable supply chains.
Today, the industry is rapidly shifting toward biologics, cell therapies, gene therapies, and one of the fastest-growing therapeutic categories of all: Antibody Drug Conjugates (ADCs). While ADCs are creating tremendous clinical excitement, they are also creating manufacturing challenges unlike anything many organizations have previously faced.
The reality is simple:
An ADC combines the complexity of a biologic with the precision requirements of a highly potent small molecule.
This combination creates operational, quality, regulatory, and workforce challenges that many organizations underestimate.
What Makes ADCs Different?
An ADC consists of three primary components:
A monoclonal antibody
A highly potent cytotoxic payload
A chemical linker that joins them together
Each component presents its own manufacturing challenges. Individually, these processes are already difficult. Combined, they create one of the most complex manufacturing platforms in the pharmaceutical industry. Organizations are no longer managing one manufacturing process. They are managing three separate manufacturing disciplines that must perform flawlessly together.
Challenge #1: The Collision of Biologics and Potent Compound Manufacturing
Traditional biologics facilities are designed around:
Cell culture; Protein purification; Sterile processing; Cold chain management.
Highly potent active pharmaceutical ingredient (HPAPI) facilities are designed around:
- Occupational safety
- Containment
- Toxicology controls
- Environmental monitoring
- Specialized cleaning validation
ADC manufacturing requires both.
Many companies discover that expertise in one area does not automatically translate to expertise in the other. A world-class biologics operation may have little experience handling highly potent compounds. Likewise, an organization experienced with potent compounds may lack deep biologics expertise. The result is a significant operational learning curve.
Challenge #2: Process Integration
Manufacturing an ADC is not simply about producing three components. The challenge is bringing them together consistently.
The conjugation step introduces unique risks:
- Drug-to-antibody ratio (DAR) variability
- Aggregation
- Stability concerns
- Product heterogeneity
- Yield loss
Small process variations can have a significant impact on product performance. This means process characterization becomes dramatically more important. Organizations must understand not only critical process parameters but also how interactions between biologic and chemical manufacturing operations affect product quality.
Challenge #3: Supply Chain Complexity
Many ADC programs rely on multiple suppliers and manufacturing partners. A typical ADC supply chain may involve:
One organization is manufacturing the antibody; another is manufacturing the payload; a third is conducting conjugation; and a fourth performing fill-finish.
Each handoff introduces risk.
Every transfer creates opportunities for:
- Data integrity issues
- Documentation errors
- Material variability
- Shipping excursions
- Quality agreement failures
As a result, tech transfer excellence becomes a strategic capability rather than simply an operational activity.
Challenge #4: Inspection Readiness
Regulators understand the complexity of ADC manufacturing. As a result, inspections often focus heavily on:
- Process understanding
- Contamination control
- Data integrity
- Cleaning validation
- Change management
- Cross-site quality oversight
For organizations using multiple CDMOs, regulators increasingly expect clear ownership and oversight of outsourced activities. A sponsor cannot simply point to a manufacturing partner when issues arise. The sponsor remains accountable. Organizations that fail to establish robust governance structures frequently discover this reality during regulatory inspections.
Challenge #5: Workforce Development
Perhaps the most underestimated challenge is workforce readiness.
The industry faces an unprecedented shortage of personnel with expertise spanning:
- Biologics manufacturing
- HPAPI handling
- Sterility assurance
- Process validation
- Regulatory compliance
- Finding individuals with experience across all these disciplines is difficult.
- Training them is even harder.
As ADC manufacturing scales globally, workforce capability may become the primary bottleneck to growth. Organizations investing in immersive learning, simulation-based training, and accelerated knowledge transfer programs will likely gain a significant competitive advantage.
Challenge #6: Commercial Scale-Up
Many ADC processes perform successfully at clinical scale. Commercial scale is a different challenge. As production volumes increase, organizations often encounter:
- Conjugation variability
- Equipment limitations
- Yield challenges
- Supply chain constraints
- Process robustness concerns
Commercialization does not create manufacturing problems. It exposes manufacturing problems that already existed. The first commercial batches often reveal process weaknesses that remained hidden during development. This is why commercial readiness planning must begin years before launch.
The Organizations That Will Win
The most successful ADC manufacturers will not simply be those with the newest facilities or largest investments.
They will be the organizations that successfully integrate:
- Process science
- Quality systems
- Workforce development
- Technology transfer excellence
- Supply chain governance
- Inspection readiness
The winners will treat manufacturing as a strategic capability rather than a support function.
Because in the ADC era, manufacturing excellence is no longer just an operational advantage.
It is a competitive advantage.
Final Thought
The pharmaceutical industry's transition from small molecules to biologics is already reshaping manufacturing.
The rise of ADCs is accelerating that transformation. Organizations that build the quality systems, technical capabilities, workforce readiness, and operational discipline required to support ADC manufacturing today will be the companies that lead the industry tomorrow.
How QxP Can Help
Quality Executive Partners (QxP) helps biopharma companies, CDMOs, and emerging ADC developers navigate the unique challenges of commercialization and manufacturing scale-up. From tech transfer and process validation to inspection readiness, contamination control, workforce development, and quality transformation, QxP provides experienced practitioners who work alongside your teams using our proven "Teach & Do" methodology.
If your organization is preparing for ADC development, technology transfer, commercial launch, or regulatory inspection, contact QxP to learn how we can help accelerate readiness
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
